Research > Urology > Sexual Health
|
|
A meta-analysis of extracorporeal shock wave therapy for Peyronie’s disease - (International Journal of Impotence Research 2016) - Peyronie’s disease (PD) is a relatively common disorder originating from connective tissue and characterized by progressively fibrotic plaques in the penile tunica albuginea. More..
Extracorporeal shock wave therapy (ESWT) in urology:a systematic review of outcome in Peyronie’s disease, erectile
dysfunction and chronic pelvic pain - (Grzegorz Lukasz Fojeck · Stefan Tiessen · Palle Jörn Sloth Osther 2017) - The objective was to evaluate high-level evidence studies of extracorporeal shock wave therapy (ESWT) for urological disorders. More...
dysfunction and chronic pelvic pain - (Grzegorz Lukasz Fojeck · Stefan Tiessen · Palle Jörn Sloth Osther 2017) - The objective was to evaluate high-level evidence studies of extracorporeal shock wave therapy (ESWT) for urological disorders. More...
Minimally invasive treatment of Peyronie's disease: evidence-based progress - (Department of Urology, Eastern Virginia Medical School, Norfolk, VA, *Division of Urologic Surgery, University of North Carolina, Chapel Hill, NC, and †Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA) - Peyronie’s disease (PD) is often physically and psychologically devastating for patients, and the goal of treatment is to improve symptoms and sexual function without adding
treatment-related morbidity. More..
treatment-related morbidity. More..
Extracorporeal Shock Wave Therapy in Peyronie’s Disease: Results of a Placebo-Controlled, Prospective, Randomized,
Single-Blind Study - (Georgios Hatzichristodoulou, MD, Christoph Meisner, PhD, Jürgen E. Gschwend, MD,
Arnulf Stenzl, MD, and Sven Lahme, MD) - Primary end point was decrease of pain between baseline and after 4 weeks follow-up. Secondary end points were changes in deviation, plaque size, and sexual function. Pain was assessed by a visual analog
scale. Deviation was measured by a goniometer after artificial erection using Alprostadil (Viridal®, Schwarz Pharma,
Monheim, Germany). Plaque size was measured with a ruler and sexual function assessed by a scale regarding the
ability to perform sexual intercourse. More..
Single-Blind Study - (Georgios Hatzichristodoulou, MD, Christoph Meisner, PhD, Jürgen E. Gschwend, MD,
Arnulf Stenzl, MD, and Sven Lahme, MD) - Primary end point was decrease of pain between baseline and after 4 weeks follow-up. Secondary end points were changes in deviation, plaque size, and sexual function. Pain was assessed by a visual analog
scale. Deviation was measured by a goniometer after artificial erection using Alprostadil (Viridal®, Schwarz Pharma,
Monheim, Germany). Plaque size was measured with a ruler and sexual function assessed by a scale regarding the
ability to perform sexual intercourse. More..
Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled
double-blind trial -(Sudhanshu Chitale, Mohammed Morsey, Louise Swift* and Krishna Sethia
Department of Urology, Norfolk & Norwich University Hospitals NHS Foundation Trust, and *Department of Medical
Statistics, School of Medicine Health Policy and Practice, University of East Anglia, Norwich, UK) - To assess the role of extracorporeal shock wave therapy (SWT), in a prospective randomized controlled trial, comparing limited SWT vs sham therapy in men with Peyronie’s disease. More..
double-blind trial -(Sudhanshu Chitale, Mohammed Morsey, Louise Swift* and Krishna Sethia
Department of Urology, Norfolk & Norwich University Hospitals NHS Foundation Trust, and *Department of Medical
Statistics, School of Medicine Health Policy and Practice, University of East Anglia, Norwich, UK) - To assess the role of extracorporeal shock wave therapy (SWT), in a prospective randomized controlled trial, comparing limited SWT vs sham therapy in men with Peyronie’s disease. More..
A First Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating Extracorporeal
Shock Wave Therapy for the Treatment of Peyronie ’s Disease- (Alessandro Palmieri, Ciro Imbimbo, Nicola Longo, Ferdinando Fusco, Paolo Verze, Francesco Mangiapia, Massimiliano Creta , Vincenzo Mirone Department of Urology, University Federico II of Naples, Naples, Italy) - Extracorporeal shock wave therapy (ESWT) is a conservative therapy
for patients with Peyronie’s disease (PD). More..
Shock Wave Therapy for the Treatment of Peyronie ’s Disease- (Alessandro Palmieri, Ciro Imbimbo, Nicola Longo, Ferdinando Fusco, Paolo Verze, Francesco Mangiapia, Massimiliano Creta , Vincenzo Mirone Department of Urology, University Federico II of Naples, Naples, Italy) - Extracorporeal shock wave therapy (ESWT) is a conservative therapy
for patients with Peyronie’s disease (PD). More..
Role of extracorporeal shock wave therapy in management of Peyronie’s disease: A preliminary report -(Rajendra Kashinath Shimpi, Ravi Jineshkumar Jain Department of Urology and Genito-Urinary Surgery, Ruby Hall Clinic, Pune, Maharashtra, India) - Peyronie’s Disease (PD) is a disease causing psycho social trauma to the patient. Multiple treatment options are available with variable results. Extra Corporeal Shock Wave Therapy (ESWT) is a new insight into the non invasive modality of management. It focuses on the mechanism of inducing angiogenesis in the penile cavernous tissue. More..
Shockwave Therapy as First-Line Treatment for Peyronie’s Disease: A Prospective Study - (A. SKOLARIKOS, M.D., ALARGOF, M.D., RIGAS, M.D., DELIVELIOTIS, M.D. and E. KONSTANTINIDIS, M.D) - To assess in a prospective study whether shockwave therapy (SWT) is effective as a first-line treatment for Peyronie’s disease. More..
Extracorporeal Shock Wave Therapy in Peyronie’s Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study -(Urology Section, Department of Surgery, University of Catania, Catania, Department of Urology, University of Florence,
Andrology Center, Villa Donatello Hospital, Florence, Department of Urology, University of Naples, Naples, Department of Urology, Molinette Hospital, University of Turin, Turin, Department of Urology, University of Pisa, Pisa, Italy) - In this study, we aimed to determine the role of extracorporeal shockwave therapy (ESWT) in the management of Peyronie’s disease (PD). More..
Andrology Center, Villa Donatello Hospital, Florence, Department of Urology, University of Naples, Naples, Department of Urology, Molinette Hospital, University of Turin, Turin, Department of Urology, University of Pisa, Pisa, Italy) - In this study, we aimed to determine the role of extracorporeal shockwave therapy (ESWT) in the management of Peyronie’s disease (PD). More..
Peyronie’s disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men - (Eric Chung, University of Queensland, Department of Urology, Princess Alexandra Hospital, Brisbane, AndroUrology Centre, St Andrew’s War Memorial Hospital, Brisbane, QLD, Australia) - Purpose: To evaluate the efficacy, safety and patient satisfaction outcomes following low intensity extracorporeal shock wave
therapy (LiESWT) in men with Peyronie’s disease (PD) using a standardised protocol. More..
therapy (LiESWT) in men with Peyronie’s disease (PD) using a standardised protocol. More..
Stromal Vascular Fraction Combined with Shock Wave for the Treatment of Peyronie’s Disease -(Elliot B. Lander, MD, Mark H. Berman, MD, Jackie R. See, MD) - This pilot study was used to evaluate safety and subjective out-comes in a small series of Peyronie’s disease patients using a combination of autologous stromal vascular fraction (SVF) and penile shock wave treat-ments. SVF can be procured and deployed into Peyronie’s plaques, en-abling the surgeons to procure and mobilize significant numbers of both adult mesenchymal stem cells and antiinflammatory cytokines released from the adipose collagen matrix after collagen digestion. More..
